31st March 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

MSN Laboratories receives approval from the CDSCO panel for FDCs Solifenacin

MSN Laboratories has received approval from the CDSCO to manufacture and market a fixed-dose combination of Solifenacin Succinate and Mirabegron to treat overactive bladder symptoms.

Sun Pharma-Lundbeck collaborate for antidepressant medication

Sun Pharma stated that it has signed an exclusive patent licence agreement with H Lundbeck to offer Vortidif, its own version of Vortioxetine, in India.

BioNTech plans to expand anti-Omicron COVID-19 vaccine testing programme

As it claimed a profit bump from its first-generation shot, BioNTech has expanded an ongoing clinical trial programme to test new vaccinations against the prevalent Omicron coronavirus type.

Coronavirus not only infects but also replicates in the human retina, as per new study

SARS-CoV-2, the virus that causes Covid-19, mostly causes infections of the respiratory system, but it also affects other organs of the human body, including the eyes and brain.

The first Roche trial of a new cancer treatmentfailed.

Roche’s new cancer immunotherapy failed to prevent the progression of an aggressive form of lung cancer, signalling bad news for a number of competitor drug researchers working on similar molecules.

Olympic Ophthalmics' Next-Generation iTEAR100 Neurostimulation Device receives FDA Approval

FDA has approved Olympic Ophthalmics’ 510 (K) request for its second-generation iTEAR100 device, a prescription neuromodulation therapy.

CartiHeal's Agili-C knee implant received FDA premarket approval

CartiHeal announced that their Agili-C implant for treating knee joint surface lesions has obtained FDA premarket approval.

FDA has given final approval to oral testosterone undecanoate

For men with a lack or absence of endogenous testosterone or hypogonadism, the FDA has awarded final approval to an oral testosterone undecanoate treatment.

Triumeq PD has been approved by the USFDA

FDA’s clearance of the first dispersible single tablet regimen including dolutegravir broadens the range of age-appropriate HIV therapy options for children.

Vadadustat application from Akebia Therapeutics is not ready for approval

In a letter to the FDA, health regulators cited worries about the increased risk of thromboembolic events and the danger of drug induced liver harm.